Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 532-540

  Valteau Couanet, Dominique ^a   Michon, Jean ^a   Boneu, Andrée ^a   Rodary, Chantal ^a   Perel, Yves ^a   Bergeron, Christophe ^a   Rubie, Hervé ^a   Coze, Carole ^a   Plantaz, Dominique ^a   Bernard, Frédéric ^a   Chastagner, Pascal ^a   Bouzy, Jeannine ^a   Hartmann, Olivier ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IODINE 123; VINCRISTINE; ANTINEOPLASTIC AGENT; CAV PROTOCOL; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; VP P PROTOCOL; VP-P PROTOCOL;

ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEARING LOSS; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; INFANT; LYSIS; MEDICAL SOCIETY; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SCINTIGRAPHY; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; FEMALE; MALE; MULTICENTER STUDY; PATHOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CISPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; INFANT; MALE; NEOPLASM METASTASIS; NEUROBLASTOMA; NEUTROPENIA; RADIOPHARMACEUTICALS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VINCRISTINE;

EID: 20044373431     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.054     Document Type: Article

References (28)

1. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid: Children's Cancer Group. N Engl J Med 341:1165-1173, 1999
2. Ladenstein R, Philip T, Lasset C, et al: Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953-965, 1998
3. Hartmann O, Valteau-Couanet D, Vassal G, et al: Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 23:789-795, 1999
4. Frappaz D, Michon J, Coze C, et al: LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 18:468-476, 2000
5. Kushner BH, LaQuaglia MP, Bonilla MA, et al: Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12:2607-2613, 1994
6. Cheung NK, Kushner BH, LaQuaglia M, et al: N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 36:227-230, 2001
7. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
8. Ambros IM, Benard J, Boavida M, et al: Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21:2077-2084, 2003
9. Frappaz D, Bonneu A, Chauvot P, et al: Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation-The SFOP Group. Med Pediatr Oncol 34:237-241, 2000
10. Brock PR, Bellman SC, Yeomans EC, et al: Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 19:295-300, 1991
11. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
12. Kushner BH, Heller G, Kramer K, et al: Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma. Cancer 89:2122-2130, 2000
13. Coze C, Hartmann O, Michon J, et al: NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: A report from the French Society of Pediatric Oncology. J Clin Oncol 15:3433-3440, 1997
14. Hartmann O, Valteau-Couanet D, Benhamou E, et al: Stage IV neuroblastoma in patients over 1 year of age at diagnosis: Consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation. Eur J Cancer 33:2126-2129, 1997
15. Kushner BH, Yeh SD, Kramer K, et al: Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 21:1082-1086, 2003
16. Matthay KK, Edeline V, Lumbroso J, et al: Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21:2486-2491, 2003
17. Shapiro B, Gross MD: Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: Clinical implications of the use of 123I-MIBG. Med Pediatr Oncol 15:170-177, 1987
18. Carli M, Green AA, Hayes FA, et al: Therapeutic efficacy of single drugs for childhood neuroblastoma. Amsterdam, the Netherlands, Ecerpta Medica, 1982
19. Frei E III, Teicher BA, Holden SA, et al: Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 48:6417-6423, 1988
20. Cheung NK, Heller G, Kushner BH, et al: Stage IV neuroblastoma more than 1 year of age at diagnosis: Major response to chemotherapy and survival durations correlated strongly with dose intensity. Prog Clin Biol Res 366:567-573, 1991
21. Meresse V, Vassal G, Michon J, et al: Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: A phase II study from the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 11:630-637, 1993
22. Frappaz D, Michon J, Hartmann O, et al: Etoposide and carboplatin in neuroblastoma: A French Society of Pediatric Oncology phase II study. J Clin Oncol 10:1592-1601, 1992
23. Furman WL, Stewart CF, Poquette CA, et al: Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815-1824, 1999
24. Vassal G, Terrier-Lacombe MJ, Bissery MC, et al: Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 74:537-545, 1996
25. Vassal G, Pondarre C, Cappelli C, et al: DNA-topoisomerase I: A new target for the treatment of neuroblastoma. Eur J Cancer 33:2011-2015, 1997
26. Vassal G, Pondarre C, Boland I, et al: Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie 80:271-280, 1998
27. De Bernardi B, Carli M, Casale F, et al: Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: Two studies by the Italian Cooperative Group for Neuroblastoma. J Clin Oncol 10:1870-1878, 1992
28. Michon JM, Hartmann O, Bouffet E, et al: An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer 34:1063-1069, 1998